CUA 2018: Late Relapse of Testicular Cancer

Halifax, Nova Scotia (UroToday.com) Joel Sheinfeld, MD, a recognized expert in the management of testicular cancer (TCa), focused his talk on a niche topic within TCa management – the late relapse. Late relapse in TCa is defined as relapse >2 years after initial orchiectomy and definitive primary treatment. 

They recently completed an institutional study of patients with late relapse (LR) at MSKCC using their prospectively maintained database (1990-2017). They identified 157 patients with LR; 143 NSGCT and 14 seminomas. Of these patients, 30 were chemo-naïve. Patient demographics are below:

UroToday CUA 2018 Late Relapse of Testicular Cancer 1

He then sequentially went through their main findings, which I summarize below.

1. Cancer-specific survival
- 5-year CSS NSGCT: 69.1% (but median time to LR was 99.6 month)
- 5-year CSS seminoma: 78.8% (but median time to LR was 59 months)

2. The pre-and-post LR management of NSGCT
UroToday CUA 2018 Late Relapse of Testicular Cancer 2

  • This was a busy slide, but important to note that all patients are susceptible to LR
  • 19 patients just had orchiectomy and had LR on surveillance
  • 48 patients required re-do operations after initial surgery for LR – so repeat surgeries are often necessary
  • Patients who underwent surgery generally did better: 5-year CSS ~75% vs. 29% (no surgery)
3. NSGCT sites of LR
- 95% were nodal metastases, and 88% were retroperitoneal – primary site of LR
- 28% had visceral metastases

4. Predictors of CSS

- While there were many preclinical univariate predictors of CSS, the only predictor of MV analysis was prior chemotherapy receipt – patients who had received prior CTX did much worse! (HR 5.6, p<0.05)
- Patients not treated with surgery post-LR and those with viable cancer and SMT fared much worse than surgically treated patients and patients with teratoma

5. Surgery for LR
- 123 (86%) underwent surgery for LR; 48 (58.5%) required a re-do RPLND
- Adjunctive procedures were often required

6. Histology at LR surgery
- Yolk sac (50%), teratoma (68.6%), somatic transformation (21%) were the most prominent histology at the time of LR; fibrosis 3.7% 

7. Sites of relapse and treatment were associated with survival
UroToday CUA 2018 Late Relapse of Testicular Cancer 3

8. Time to LR

- Occurred as late as 38 years later – so lifelong monitoring is required
- CSS was not dependent on time to LR – no time cutoff identified as a predictor of better/worse CSS
- However, SMT was noted to develop later than viable tumor or teratoma

What is the etiology of LR? In Sheinfeld’s opinion, it is the result of a vulnerable retroperitoneum – which is due to (depending on initial presentation): 

UroToday CUA 2018 Late Relapse of Testicular Cancer 4
He then reviewed some additional studies to highlight the following points:

1. Even Stage 1 tumors are at risk for LR (2.5-5% in the Mortensen EU 2016 paper)
2. Clinical T1a vs. T1b – T1a tend to have a higher rate of LR; but the LR in T1b tend to be more aggressive. (Kollmannsberger JCO 2014)
3. Template dissection is a disservice to the patient – MSKCC outcomes improved once they abandoned template dissections in 1998 (Stephenson JCO 2005, Carver JCO 2007)
4. “Relapsers relapse” – unfortunately, the patients that relapsed early are more likely to relapse late!

His take-home points are:
UroToday CUA 2018 Late Relapse of Testicular Cancer 5

Presented by: Joel Sheinfeld, MD, Memorial Sloan Kettering Cancer Center, NYC, New York

Written By: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto   Twitter: @tchandra_uromd at the 73rd Canadian Urological Association Annual Meeting - June 23 - 26, 2018 - Halifax, Nova Scotia
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe